气血和方通过稳定EIF4A3逆转circRNA介导的血管新生抑制改善冠心病心肌梗死
本研究探讨气血和方(QBHF)治疗冠心病心肌梗死的血管新生机制。采用高脂饮食ApoE-/-小鼠左前降支结扎模型及缺氧内皮细胞模型,结合液质联用、生物信息学和实验验证。结果显示QBHF剂量依赖性改善心功能、减轻心肌损伤并上调血管新生标志物;机制上通过抑制hsa_circ_0003296、稳定EIF4A3,延长VEGFA和VEGFR2 mRNA半衰期促进血管新生。
要点
- 气血和方剂量依赖性改善AS-MI小鼠心功能并减轻心肌损伤。
- QBHF抑制hsa_circ_0003296,阻止EIF4A3泛素化降解。
- 稳定EIF4A3延长VEGFA和VEGFR2 mRNA半衰期,促进血管新生。
核心结论
- 气血和方通过逆转hsa_circ_0003296介导的血管新生抑制来改善冠心病心肌梗死。
- 该过程通过稳定EIF4A3、增强VEGFA和VEGFR2 mRNA稳定性来实现。
研究设计与样本
- 采用高脂饮食喂养的ApoE-/-小鼠行左前降支冠状动脉结扎建立AS-MI模型。
- 体外采用缺氧诱导的EA.hy926内皮细胞模型。
- 通过液质联用表征QBHF化学成分,并结合组织学、功能学和分子学检测及生物信息学验证机制。
主要发现
- 在AS-MI小鼠中,QBHF剂量依赖性改善心功能、减轻心肌损伤并上调血管新生标志物。
- 体外实验中,QBHF增强缺氧诱导的EA.hy926细胞增殖、迁移和成管能力。
- hsa_circ_0003296在AS和MI患者外周血中显著上调,直接结合EIF4A3并促进其泛素介导的降解。
- QBHF抑制hsa_circ_0003296表达,阻止EIF4A3降解,进而延长VEGFA和VEGFR2的mRNA半衰期。
关键数值与推荐
- 化学分析鉴定QBHF中67种化合物,并对8种主要成分进行定量。
临床怎么用
- 气血和方可能通过促进血管新生改善冠心病心肌梗死,尤其适用于存在hsa_circ_0003296上调的患者。
- 临床可考虑将hsa_circ_0003296作为潜在生物标志物,用于筛选气血和方获益人群。
局限性
- 机制主要在动物模型和细胞模型中验证,尚需临床研究确认。
- hsa_circ_0003296作为生物标志物的敏感性和特异性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocardial infarction (MI) is the most severe clinical complication of coronary atherosclerotic heart disease (CHD), representing a leading cause of global morbidity and mortality. Qi-Blood Harmony Formula (QBHF), a traditional Chinese medicine, has shown clinical promise for managing MI; however, its underlying mechanisms remain to be fully elucidated. PURPOSE: This study aimed to explore the therapeutic mechanism of QBHF against MI in the context of CHD, with a specific focus on its role in angiogenesis. METHODS: QBHF chemical components were characterized by ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry. Therapeutic efficacy was evaluated in a high-fat diet-fed ApoE-/- mouse model with left anterior descending coronary artery ligation and in a hypoxia-induced endothelial cell model. Cardiac function and angiogenesis were assessed through histological, functional, and molecular assays, with the underlying mechanisms further investigated using bioinformatics and experimental validation. RESULTS: Chemical profiling identified 67 compounds in QBHF, with eight major constituents quantified. In atherosclerosis-myocardial infarction (AS-MI) mice, QBHF dose-dependently improved cardiac function, attenuated myocardial injury, and upregulated angiogenic markers. In vitro, QBHF enhanced hypoxia-induced proliferation, migration, and tube formation in EA.hy926 cells. Mechanistically, a specific circular RNA (hsa_circ_0003296) was found to be significantly upregulated in the peripheral blood of AS and MI patients. It directly bound to eukaryotic initiation factor 4A-III (EIF4A3) to promote its ubiquitin-mediated degradation. QBHF suppressed hsa_circ_0003296 expression, thereby preventing EIF4A3 degradation. The stabilized EIF4A3 subsequently prolonged the mRNA half-lives of vascular endothelial growth factor A (VEGFA) and VEGF receptor 2 (VEGFR2), thereby promoting angiogenesis. CONCLUSIONS: These results suggest that QBHF ameliorates MI in CHD by reversing hsa_circ_0003296-mediated inhibition of angiogenesis. This process is executed through the stabilization of EIF4A3, which enhances the mRNA stability of VEGFA and VEGFR2.
引用
- Huang M, Guo H, Chen J, et al. Qi-Blood Harmony Formula ameliorates myocardial infarction in coronary atherosclerotic heart disease by reversing circRNA-mediated inhibition of angiogenesis via EIF4A3 stabilization. Phytomedicine. 2026. PMID: 42090954. doi:10.1016/j.phymed.2026.158226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。